121 related articles for article (PubMed ID: 26005938)
1. [Pharmacogenetics of immunosuppressants].
Cojutti PG; Baraldo M
G Ital Nefrol; 2015; 32(2):. PubMed ID: 26005938
[TBL] [Abstract][Full Text] [Related]
2. New challenges and promises in solid organ transplantation pharmacogenetics: the genetic variability of proteins involved in the pharmacodynamics of immunosuppressive drugs.
Pouché L; Stojanova J; Marquet P; Picard N
Pharmacogenomics; 2016 Feb; 17(3):277-96. PubMed ID: 26799749
[TBL] [Abstract][Full Text] [Related]
3. Genes and beans: pharmacogenomics of renal transplant.
Murray B; Hawes E; Lee RA; Watson R; Roederer MW
Pharmacogenomics; 2013 May; 14(7):783-98. PubMed ID: 23651025
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, Pharmacodynamics and Pharmacogenomics of Immunosuppressants in Allogeneic Haematopoietic Cell Transplantation: Part I.
McCune JS; Bemer MJ
Clin Pharmacokinet; 2016 May; 55(5):525-50. PubMed ID: 26563168
[TBL] [Abstract][Full Text] [Related]
5. Everolimus: a guide to its use in liver transplantation.
Keating GM; Lyseng-Williamson KA
BioDrugs; 2013 Aug; 27(4):407-11. PubMed ID: 23696253
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetics in kidney transplantation: recent updates and potential clinical applications.
Elens L; Hesselink DA; van Schaik RH; van Gelder T
Mol Diagn Ther; 2012 Dec; 16(6):331-45. PubMed ID: 23192462
[TBL] [Abstract][Full Text] [Related]
7. Practicability of pharmacogenetics in transplantation medicine.
van Gelder T; van Schaik RH; Hesselink DA
Clin Pharmacol Ther; 2014 Mar; 95(3):262-4. PubMed ID: 23995265
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetics of immunosuppressive drugs: prospect of individual therapy for transplant patients.
Ekbal NJ; Holt DW; Macphee IA
Pharmacogenomics; 2008 May; 9(5):585-96. PubMed ID: 18466104
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics of immunosuppressants: progress, pitfalls and promises.
Cattaneo D; Baldelli S; Perico N
Am J Transplant; 2008 Jul; 8(7):1374-83. PubMed ID: 18510642
[TBL] [Abstract][Full Text] [Related]
10. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
Tönshoff B; Höcker B
Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
[TBL] [Abstract][Full Text] [Related]
11. Biotransformation enzymes and drug transporters pharmacogenetics in relation to immunosuppressive drugs: impact on pharmacokinetics and clinical outcome.
Mourad M; Wallemacq P; De Meyer M; Malaise J; De Pauw L; Eddour DC; Goffin E; Lerut J; Haufroid V
Transplantation; 2008 Apr; 85(7 Suppl):S19-24. PubMed ID: 18401258
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients.
Oh CK; Huh KH; Ha J; Kim YH; Kim YL; Kim YS
Transplantation; 2015 Jan; 99(1):180-6. PubMed ID: 24983307
[TBL] [Abstract][Full Text] [Related]
13. Current progress in pharmacogenetics and individualized immunosuppressive drug dosing in organ transplantation.
Ware N; MacPhee IA
Curr Opin Mol Ther; 2010 Jun; 12(3):270-83. PubMed ID: 20521216
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetics in solid organ transplantation: current status and future directions.
de Jonge H; Kuypers DR
Transplant Rev (Orlando); 2008 Jan; 22(1):6-20. PubMed ID: 18631854
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenomics: the key to improved drug therapy in transplant patients.
Burckart GJ
Clin Lab Med; 2008 Sep; 28(3):411-22, vi. PubMed ID: 19028260
[TBL] [Abstract][Full Text] [Related]
16. Proliferation signal inhibitors in cardiac transplantation.
Gustafsson F; Ross HJ
Curr Opin Cardiol; 2007 Mar; 22(2):111-6. PubMed ID: 17284989
[TBL] [Abstract][Full Text] [Related]
17. Drug therapy in the heart transplant recipient: part II: immunosuppressive drugs.
Lindenfeld J; Miller GG; Shakar SF; Zolty R; Lowes BD; Wolfel EE; Mestroni L; Page RL; Kobashigawa J
Circulation; 2004 Dec; 110(25):3858-65. PubMed ID: 15611389
[No Abstract] [Full Text] [Related]
18. Evaluation of the novel protein kinase C inhibitor sotrastaurin as immunosuppressive therapy after renal transplantation.
Matz M; Naik M; Mashreghi MF; Glander P; Neumayer HH; Budde K
Expert Opin Drug Metab Toxicol; 2011 Jan; 7(1):103-13. PubMed ID: 21142580
[TBL] [Abstract][Full Text] [Related]
19. Pediatric aspects of therapeutic drug monitoring of mycophenolic acid in renal transplantation.
Tönshoff B; David-Neto E; Ettenger R; Filler G; van Gelder T; Goebel J; Kuypers DR; Tsai E; Vinks AA; Weber LT; Zimmerhackl LB
Transplant Rev (Orlando); 2011 Apr; 25(2):78-89. PubMed ID: 21454065
[TBL] [Abstract][Full Text] [Related]
20. Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation.
Cibrik D; Silva HT; Vathsala A; Lackova E; Cornu-Artis C; Walker RG; Wang Z; Zibari GB; Shihab F; Kim YS
Transplantation; 2013 Apr; 95(7):933-42. PubMed ID: 23422495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
